De Novo esophageal neoplasia after liver transplantation

Liver Transplantation

Volumn 13, Issue 3, 2007, Pages 443-450

  Presser, Sabine J ^a   Schumacher, Guido ^a   Neuhaus, Ruth ^a   Thuss Patience, Peter ^a   Stieler, Jens ^a   Neuhaus, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CISPLATIN; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; HEART NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33947403641     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21058     Document Type: Article

References (52)

1. Karam VH, Gasquet I, Delvart V, Hiesse C. Dorent R. Danet C, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003;76:1699-1704.
2. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schulger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000;69:781-789.
3. Fung JJ, Jaln A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation a major cause of late death. Liver Tnanspl 2001;7:S109-S118.
4. Roayaie S, Schwartz JD, Sung MW, Emre, SHm Miller CM, Gondolesi GE, et al. Recurrence of hepatecellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;534-540.
5. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232:490-500.
6. Pruthl J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-815.
7. Sanchez W. Talwalkar JA, Gores GJ. Will all liver transplantation patients eventually die from cancer? J Hepatol 2006:44:13-18.
8. Starzl TE, Five years experience in renal transplantation with immunosuppresive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968;168:416.
9. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1;106-112
10. McKhann CF. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 1969;8:209-212.
11. Penn I. Neoplastic, complications of transplantation. Semin Respir Infect 1993;233-239.
12. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89:1221-1227.
13. Lee ES, Locker J, Nalesnik M, Reyes J. Jaffe R. Alashari M, et al. The association of Epstein-Barr virus with, smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995;332:19-25.
14. Timmons CF, Dawson DB, Richards CS, Andrew, WS, Katz JA. Epstein-Barr virus-associated leiomyosarcomas in liver transplantation recipients. Origin from either donor or recipient tissue. Cancer 1995;76:1481-1489.
15. Kelly DM, Emre S, Guy SR, Miller CM. Schwart ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998;83:1237-1243.
16. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagaman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397: 530-534.
17. Jonas S, Rayes N, Neumann U, Neuhaus R. Bechstein WO. Guckelberger O. et al. De novo malignancies after live trasplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globlin. Cancer 1997;80:1141-1150.
18. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990:323:1767-1769.
19. Penn I. The problem of cancer in organ transplantation recipients: an overview. Transplant Sci 1994;4:23-32.
20. Yao F, Ahuja J, Savides T, Behling C, Li S, Hart M. Rapid progression of gastroesophageal junction adenocarcinoma after liver transplantation. J Clin Gastroenterol 1997:24:54-55.
21. Safidi R, Ilan Y, Eid A, et al. Solid tumors after liver, transplantation. Transplant Proc 1999;31:1894-1895.
22. Ilan Y, Shouval D, Galun E, et al. Esophageal malignancy after liver transplantation in a patient with Barrett's esophagus. Scand J Gastroenterol 1996:31:415-416.
23. Trotter JF. Brazer SR. Rapid progression to high-grade dysplasia in Barrett's esophagus after liver transplantation. Liver Transpl Surg 1999;5:332-333.
24. Diaz de Liano A, Artieda C, Yarnoz C, Garde C, Flores L, Ortiz H. Esophageal squamous cell carcinoma after liver transplantation. Clin Transl Oncol 2005;7:518-520.
25. Scobey MW. Kerr BJ, Geisinger KR, Hamilton RW, Richter JE. Squamous cell carcinoma of the esophagus in association with long-term immunosuppressive therapy. South Med J 1987;80:1587-1589.
26. Feczko PJ, Mezwa DG. Gastrointestinal carcinomas in renal transplant recipients. Gastrointest Radiol 1991;16: 351-353.
27. Schumacher G. Oldtmann M. Rueggeberg A, Jacob D, Jonas S, Langrehr JM, et al. Sirolimus inhabits growth of human hepatoma cells alone or combined with tacrolimus, while tarcolimus promotes cell growth. World J Gastroenterol 2005;11:1420-1425.
28. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular, carcinoma. Liver Transpl 2004; 10;1301-1311.
29. Benlloch S, Berenguer M, Prieto M, Moreno R, San Juan F, Rayon M et al. De novo Internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004;4:596-604.
30. Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F. Rotellar F, et al. De novo neoplasla after liver transplantation an analysis of risk factors and influence on survival. Liver Transpl 2005;11:89-97.
31. Duvoux C. Delacroix I, Richardet JP, Roudot-Thoraval F, Metreau JM, Fagniez PL, et al. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 1999; 67:418-421.
32. Kenngott S, Gerbes AL, Schauer R, Bilzer M. Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-indured cirrhosis. Transpl Int 2003;16:639-641.
33. Brown LM, Hoover R, Silverman D, et al. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidermiol 2001;153:114-122.
34. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252.
35. Yu MC, Garabrant DH, Peters JM.,Mack TM. Tobacco, alcohol, diet, occupation, and carcinoma of the esophagus. Cancer Res 1988:48:3843-3848.
36. Terry P, Lagergren J, Ye W, Nyren O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 2000;87:750-754.
37. Alkan S, Karcher DS, Otiz A, Khalil S. Akhtar M, Ali MA. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus in organ transplant patients with immunosupression. Br J Haematol 1997;96:412-414.
38. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: Interview study from the Third National Cancer Survey. J Natl Cancer Inst 1977;58:525-547.
39. Zaman A, Hapke R, Flora K, Rosen H, Benner K. Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation. Am J Gastroenterol 1999;94:895-899.
40. Nicolas Perez D, Quintero E, Parra, Blanco A, Screening the at-risk population for squamous cell carcinoma of the esophagus. Gastroenterol Hepatol 2005;28:337-346. [Spanish].
41. Slewert JR, Feith M, Stein HJ. Esophagectomy as therapeutic principle for squamous cell esophageal cancer. Chirurg 2005:76:1033-1043, [German].
42. Michelet P, D'Journo XB, Roch A, Papazian, L, Ragni J, Thomas P, et al. Perioperative risk factors for anastomotic leakage after esophagectomy: influence of thoraric epidural analgesia. Chest 2005;128;3461-3466.
43. Alanezi K, Urschel JD. Mortality secondary to esophageal anastomatic leak. Ann Thorac Cardivasc Surg 2004;10: 71-75.
44. Anikin VA, McManus KG, Graham AN, McGuigan JA. Total thoraric esophagectomy for esophageel cancer. J Am Coll Surg 1997;185:525-529.
45. Choi HK, Law S, Chu KM, Wong J. The value of neck drain in esophageal surgery: a randomized trial. Dis Esophagus 1998;11:40-42.
46. Gupta NM. Oesophagectomy without thoracotomy: First 250 patients. Eur J Surg 1996;162:455-461.
47. Law S, Fok M, Chu KM, Wong J. Comparison of hand-sewn and stapled esophagogastric anastomasis after esophageal resection for cancer: a prospective randomized controlled trial. Ann Surg 1997;226:169-173.
48. van Lanschot JJ, van Blankenstein M, Oel HY, Tilanus HW. Randomized comparison of preverbral and retrosternal gastric tube reconstruction after resection of oesophageal carcinoma. Br J Surg 1999;86:102-108.
49. Zleren HU, Muller JM, Pichlmaier H. Prospective randomized study of one- or two-layer anastomosis following oesophageal resection and cervical oesophagastrostomy. Br J Surg 1993;80:608-611.
50. Ferguson MK, Martin TF, Reeder LB, Olak J. Mortality after esophagectomy: risk factor analysis. World J Surg 1997:21:599-603: discussion 603-594.
51. Jamieson GG, Mathew G. Ludemann R, Wayman J. Myers JC, Devitt PG. Postoperative mortality folloving oesophagectomy and problem reporting its rate. Br J Surg 2004;91:943-947.
52. Fletkau R. Definitive and neoadjuvant radiochemotherapy of squamous cell carcinomas of the oesophagus. Onkologie 2004;27:39-44.